|Bid||80.05 x 100|
|Ask||81.90 x 100|
|Day's Range||77.67 - 80.87|
|52 Week Range||28.82 - 84.37|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Sarepta Therapeutics (SRPT) posted $231.9 million in operating activities in fiscal 2017 compared with $245.8 million in fiscal 2016. This decrease of $13.8 million in fiscal 2017 was primarily due to a decrease of $91.6 million in a net loss. This trend was driven by higher product revenues of Exondys and a decrease in research and development expenses due to capitalization of inventory.
How Is Sarepta Therapeutics Positioned in 2018? Sarepta Therapeutics (SRPT) generated revenues of $154.5 million in fiscal 2017 compared with $5.4 million in fiscal 2016. The substantial increase in revenues shows the increasing demand for the product.
How Is Sarepta Therapeutics Positioned in 2018? Sarepta Therapeutics’ (SRPT) Exondus was granted accelerated approval by the FDA in September 2016. Sarepta Therapeutics’ golodirsen is an exon 53 skipping drug candidate.
How Is Sarepta Therapeutics Positioned in 2018? Sarepta Therapeutics (SRPT) is a commercial stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics, gene therapy, and other genetic approaches for treating rare neuromuscular diseases. Of the 19 analysts covering Sarepta Therapeutics in April 2018, six analysts gave the stock a “strong buy” rating, 11 analysts gave it a “buy” rating, and two analysts gave it a “hold” rating.
Short interest is high for SRPT with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting SRPT. The net inflows of $171 million over the last one-month into ETFs that hold SRPT are among the lowest of the last year and appear to be slowing.
All three companies are developing drugs made up of a shortened version of the dystrophin gene, which normally protects muscle cells but is absent in boys with Duchenne.
Short interest is high for SRPT with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting SRPT. Over the last month, ETFs holding SRPT are favorable, with net inflows of $3.08 billion.
Sarepta Therapeutics (SRPT) stock has risen 19.3%, from $62.11 on March 1, 2018, to $74.09 on March 29, 2018. Its less-than-expected loss in 4Q17, mainly due to solid sales of EXONDYS 51 and nearly double the projected sales for EXONDYS 51 in fiscal 2018 compared to fiscal 2017, catapulted the stock from $62.11 on March 1, 2018, to $71.45 on March 5, 2018. On April 4, 2018, Sarepta Therapeutics was trading 263% above its 52-week low of $28.14 and 12.3% below its 52-week high of $84.37.
The biopharmaceutical company, which won controversial FDA approval for a Duchenne Muscular Dystrophy drug, now confronts patient groups asking HHS to take its patents and drop the price of that drug.
On March 28, 2018, Regeneron Pharmaceuticals (REGN) was trading at $344.36, a ~9.8% rise from its 52-week low of $313.53. On March 29, Regeneron stock closed at $344.36, which represented a ~7.2% rise from its share price in the week ended March 23, 2017. On March 21, 2018, Regeneron Pharmaceuticals announced a collaboration agreement with Alnylam Pharmaceuticals (ALNY) for the identification of RNA interference therapeutics for the treatment of chronic liver disease NASH (non-alcoholic steatohepatitis) and other related diseases.
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Cambridge biotech raised $125 million in an IPO in January, but saw its stock price plummet earlier this month after disclosing that the FDA had halted a trial of the drug.
Multiple small- and mid-cap biotech stocks have benefited from a strong run, prompting Morgan Stanley to downgrade three companies in the group. The Analyst Morgan Stanley's Matthew Harrison downgraded ...
In light of Monday's volatility, here are five stocks to watch this week according to VantagePoint , a platform that uses artificial intelligence and Intermarket analysis to predict price movement. What's ...
The development, which follows a partial clinical hold on the same product last year, raises ‘multiple concerns,’ J.P. Morgan analysts said.
Sarepta extended its lead in Duchenne muscular dystrophy on Thursday as new rival Solid Biosciences cratered after the FDA placed its trial on a clinical hold.
Shares of Sarepta Therapeutics (SRPT) are higher on Thursday, after rival Solid Biosciences' (SLDB) microdystrophin gene transfer program for Duchenne muscular dystrophy (DMD), was put on clinical hold. Solid Biosciences had to pause its IGNITE DMD clinical trial on safety concerns, after the first patient who received the gene therapy about a month ago was hospitalized due an unexpected event, including a reduced red-blood-cell count. Although the patient is recovering, Solid Biosciences reported the incident, given that it was unexpected, leading to the hold. W.C. Wainwright's Debjit Chattopadhyay reiterated a Buy rating and $92 price target on Sarepta today, writing that given the differences in the drugs and their evolving safety profiles, Solid Biosciences's setback looks like good news for Sarepta, which investors should buy "in the event of any collateral damage stemming from the Solid Biosciences clinical hold." He argues that the news will fortify the perception that Solid Biosciences' offering is a "potentially risky alternative" to Sarepta's competing investigational drug, and it may make it harder for Solid Biosciences to enroll patients in trials, especially if Sarepta continues to report positive news.
Shares of Solid Biosciences (SLDB) were hit after the FDA put a clinical hold on a phase III study of lead DMD candidate, SGT-001.
Less than two months after pulling off one of the biggest initial public offerings for a local biotech in recent years, Cambridge-based Solid Biosciences said that the FDA had halted a trial of its gene therapy treatment for Duchenne muscular dystrophy, sending shares of the company into a tailspin. Solid (SLDB) said Wednesday that the FDA had stopped an early-stage study of the drug after one patient was hospitalized due to reduced platelet and red blood cell count. "The team at Solid will be working with the principal investigator and FDA to fully understand the cause and nature of this event, as well as identify appropriate next steps as soon as possible," the company said in a statement.